Targeted Therapies in CLL: Monotherapy Versus Combination Approaches

@article{Khan2018TargetedTI,
  title={Targeted Therapies in CLL: Monotherapy Versus Combination Approaches},
  author={M. Khan and T. Siddiqi},
  journal={Current Hematologic Malignancy Reports},
  year={2018},
  volume={13},
  pages={525-533}
}
  • M. Khan, T. Siddiqi
  • Published 2018
  • Medicine
  • Current Hematologic Malignancy Reports
  • Purpose of ReviewWhile chemoimmunotherapy has improved outcomes in chronic lymphocytic leukemia (CLL), it is not curative, has significant relapse rates, and is not always well tolerated. Recently, novel targeted therapies have been developed to increase response rates and reduce toxicity, especially in high-risk disease. Current goals of CLL therapies are to produce deep and durable, especially minimal residual disease (MRD)-negative, remissions so as to allow patients to ultimately… CONTINUE READING
    6 Citations

    References

    SHOWING 1-10 OF 46 REFERENCES
    Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
    • 1,298
    • Highly Influential
    • PDF
    Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
    • 993
    • PDF
    Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia.
    • B. Cheson, J. Byrd, +5 authors T. Kipps
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2012
    • 160
    Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.
    • 167
    • Highly Influential
    Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
    • 412
    Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    • 1,058
    • PDF